MilliporeSigma Establishes Sheboygan, Wisconsin, Membrane Production Facility
07/21/2022
The new facility is supported by a $136.7 million contract award from the U.S. Department of Defense (DoD), on behalf of the U.S. Department of Health and Human Services. Lateral flow membranes are a key component in rapid diagnostic test kits for a variety of applications, including Covid-19 testing, according to company officials.
"Our purpose is to positively impact life and health with science, and today's ground-breaking exemplifies this commitment by adding physical capacity and expanding our regional network to meet the growing needs of our customers and ensure supply chain security," said Matthias Heinzel, Member of the Executive Board of Merck KGaA, Darmstadt, Germany, and CEO Life Science. "This new, state-of-the-art facility will support the surge in demand experienced by our global in-vitro diagnostic manufacturing customers."
Once built, the lateral flow membrane facility will be MilliporeSigma's first facility in the United States capable of producing diagnostic-grade membrane. Its location further supports the company's competitive market advantage with improved supply security and reduced lead times for global customers. The lateral flow membrane production line complements the global capacity network of the Life Science business sector of Merck KGaA, by adding redundant capabilities to its two production lines in Cork, Ireland, thereby mitigating supply chain risks.
"From COVID-19 rapid testing to cancer therapies, the work MilliporeSigma does helps promote the health and safety of our families and communities while creating good jobs for hardworking Wisconsinites, and I am glad to be celebrating their success today," said Governor Tony Evers. "In addition to creating 60 new jobs in Sheboygan, this new facility will provide a major step forward in expanding domestic diagnostic testing as the company's first lateral flow membrane production facility in the U.S., ensuring our state and country are ready to tackle any public health crisis that comes our way now and into the future."
The Life Science business sector of Merck KGaA, Darmstadt, Germany, said it is continuing to invest in products and technologies across its portfolio that are key to manufacturing novel therapies, vaccines and diagnostics. All expansions and investments are part of an ambitious, multi-year program to increase the industrial capacity and capabilities of the Life Science business sector to support the growing global demand for lifesaving medications and to make significant contributions to public health.
Project Announcements
Japan-Based YKK AP America Plans Macon, Georgia, Manufacturing Center
08/19/2022
CF Industries Holdings-Mitsui Plan Ascension Parish, Louisiana, Carbon Capture Ammonia Plant
08/19/2022
Sub-Zero Group Establishes Cedar Rapids, Iowa, Light Manufacturing Plant
08/19/2022
WuXi STA Establishes Middletown, Delaware, Pharmaceutical Manufacturing Campus
08/18/2022
Cargill Upgrades St. Martin Parish, Louisiana, Operations
08/18/2022
Pet Supplies Plus Plans Orangeburg County, South Carolina, Distribution Hub
08/18/2022
Most Read
-
The 2021 Top States for Doing Business Reflect Their Locational Advantages
Q3 2021
-
Area Development’s 17th Annual Shovel Awards Recognize State and Local Economic Development Efforts — First Two Platinum Shovels Awarded
Q2 2022
-
In Focus: “Golden Age” of Spec Development
Q3 2022
-
In Focus: Demand for Industrial Land Surges
Q2 2022
-
36th Annual Corporate Survey: Executives Focus on Labor, Energy, Shipping Costs
Q1 2022
-
Using Robust Project Controls to Enhance Project Management
Q3 2022
-
Explosive Growth of Life Sciences Sector Comes with Challenges
Q3 2022